Smart scans aim to personalize tamoxifen dosing for Drug-Resistant breast cancer

NCT ID NCT04174352

First seen Jan 11, 2026 · Last updated May 05, 2026 · Updated 16 times

Summary

This study tests whether a special PET scan (FES-PET) can help find the best dose of tamoxifen for people with metastatic breast cancer that has an ESR1 mutation. These mutations can make standard tamoxifen doses less effective. The study will enroll 12 participants and use the scan to measure how well different doses block estrogen receptors, aiming to improve treatment without requiring lifelong medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+ BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Wisconsin Oncology Network (WONIX) sites

    NOT_YET_RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.